TP53RK and non-Hodgkin lymphoma: The top two DEGs from the 250 nmol/L enitociclib 4 hours in vitro treatment (Fig. 5A, green bars) are confirmed to be reproducibly downregulated after C1D1 and C1D15 in blood samples of patients with DH-DLBCL and other MYC+ NHL at approximately –1- and –2-fold change from enitociclib predose for PHF23 and TP53RK mRNAs, respectively (Fig. 5B).